Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neurocrine Biosciences

121.82
+0.80000.66%
Volume:251.00K
Turnover:30.46M
Market Cap:12.06B
PE:41.19
High:121.93
Open:120.19
Low:120.19
Close:121.02
Loading ...

Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures

MT Newswires Live
·
16 May

BRIEF-Neurocrine Reports Late Stage Data Of Crenessity

Reuters
·
08 May

Neurocrine Biosciences Announces New Results From Exploratory Analyses of the Phase 3 Cahtalyst™ Pediatric Study Demonstrating Crenessity™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

THOMSON REUTERS
·
08 May

Neurocrine Biosciences Inc - Data Consistent Across All Patient Subgroups in Cahtalyst Study

THOMSON REUTERS
·
08 May

Director William H. Rastetter Reports Disposal of Common Shares in Neurocrine Biosciences Inc

Reuters
·
08 May

Neurocrine Biosciences’ Earnings Call Highlights Growth Amid Challenges

TIPRANKS
·
07 May

Post-Bell | U.S. Stocks Close Lower; Pony AI Soars 48%; WeRide Surges 32%; Hims & Hers Jumps 18%; Tesla Drops 2%

Tiger Newspress
·
07 May

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

Benzinga
·
07 May

Neurocrine Price Target Cut to $154.00/Share From $160.00 by Piper Sandler

Dow Jones
·
07 May

Neurocrine Biosciences Stock Rises on Revenue Beat as Ingrezza Sales Climb

Dow Jones
·
06 May

Neurocrine Biosciences Up Over 13%, on Pace for Largest Percent Increase Since November 2017 -- Data Talk

Dow Jones
·
06 May

Stock Track | Neurocrine Biosciences Soars 16.71% on Strong Q1 Earnings, INGREZZA Sales Growth, and Analyst Upgrades

Stock Track
·
06 May

Neurocrine price target raised to $130 from $115 at Wedbush

TIPRANKS
·
06 May

Wedbush Sticks to Its Buy Rating for Neurocrine (NBIX)

TIPRANKS
·
06 May

RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating

MT Newswires Live
·
06 May

Neurocrine price target raised to $165 from $155 at Guggenheim

TIPRANKS
·
06 May

Neurocrine Is Maintained at Buy by Needham

Dow Jones
·
06 May

Neurocrine Biosciences Inc : Needham Raises Target Price to $139 From $138

THOMSON REUTERS
·
06 May

Stock Track | Neurocrine Biosciences Soars 10.28% Pre-market on Strong Q1 Earnings and Analyst Upgrades

Stock Track
·
06 May

Neurocrine Biosciences Inc : Bofa Global Research Raises Price Objective to $183 From $179

THOMSON REUTERS
·
06 May